Self-Reported Improvement for Chronic Rhinosinusitis Major Symptoms in Patients Treated with Omalizumab
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Design
2.2. Study Population
2.3. Data Collection
2.4. Outcome Measures
2.5. Statistical Analysis
3. Results
3.1. Study Population
3.2. Outcome Measures
3.3. AERD
4. Discussion
5. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Chen, Y.; Dales, R.; Lin, M. The Epidemiology of Chronic Rhinosinusitis in Canadians. Laryngoscope 2003, 113, 1199–1205. [Google Scholar] [CrossRef] [PubMed]
- Caulley, L.; Thavorn, K.; Rudmik, L.; Cameron, C.; Kilty, S.J. Direct costs of adult chronic rhinosinusitis by using 4 methods of estimation: Results of the US Medical Expenditure Panel Survey. J. Allergy Clin. Immunol. 2015, 136, 1517–1522. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hong, C.J.; Tsang, A.C.; Quinn, J.G.; Bonaparte, J.; Stevens, A.; Kilty, S.J. Anti-IgE monoclonal antibody therapy for the treatment of chronic rhinosinusitis: A systematic review. Syst. Rev. 2015, 4, 166. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gliklich, R.E.; Metson, R. The health impact of chronic sinusitis in patients seeking otolaryngologic care. Otolaryngol. Neck Surg. 1995, 113, 104–109. [Google Scholar] [CrossRef]
- Fokkens, W.J.; Lund, V.J.; Mullol, J.; Bachert, C.; Alobid, I.; Baroody, F.; Cohen, N.; Cervin, A.; Douglas, R.; Gevaert, P.; et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2012. Rhinol. Suppl. 2012, 23, 1–298. [Google Scholar]
- Kilty, S.J.; McDonald, J.T.; Johnson, S.; Al-Mutairi, D. Socioeconomic status: A disease modifier of chronic rhinosinusitis? Rhinol. J. 2011, 49, 533–537. [Google Scholar]
- Macdonald, K.I.; McNally, J.D.; Massoud, E. The health and resource utilization of Canadians with chronic rhinosinusitis. Laryngoscope 2009, 119, 184–189. [Google Scholar] [CrossRef] [PubMed]
- Soler, Z.M.; Wittenberg, E.; Schlosser, R.J.; Mace, J.C.; Smith, T.L. Health state utility values in patients undergoing endoscopic sinus surgery. Laryngoscope 2011, 121, 2672–2678. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Beck, L.A.; Marcotte, G.V.; MacGlashan, D.; Togias, A.; Saini, S. Omalizumab-induced reductions in mast cell Fce psilon RI expression and function. J. Allergy Clin. Immunol. 2004, 114, 527–530. [Google Scholar] [CrossRef] [PubMed]
- Gevaert, P.; Calus, L.; Van Zele, T.; Blomme, K.; De Ruyck, N.; Bauters, W.; Hellings, P.W.; Brusselle, G.; De Bacquer, D.; Van Cauwenberge, P.; et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J. Allergy Clin. Immunol. 2013, 131, 110–116.e1. [Google Scholar] [CrossRef] [PubMed]
- Tsabouri, S.; Tseretopoulou, X.; Priftis, K.; Ntzani, E. Omalizumab for the Treatment of Inadequately Controlled Allergic Rhinitis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. J. Allergy Clin. Immunol. Pract. 2014, 2, 332–340.e1. [Google Scholar] [CrossRef] [PubMed]
- Pinto, J.; Mehta, N.; DiTineo, M.; Wang, J.; Baroody, F.; Naclerio, R. A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis. Rhinol. J. 2010, 48, 318–324. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cusack, R.; Sahadevan, A.; Lane, S. Qualitative effects of omalizumab on concomitant IgE-mediated disease in a severe asthmatic population: A real life observational study. QJM Int. J. Med. 2016, 109, 601–604. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chandra, R.K.; Clavenna, M.; Samuelson, M.; Tanner, S.B.; Turner, J.H. Impact of omalizumab therapy on medication requirements for chronic rhinosinusitis. Int. Forum Allergy Rhinol. 2015, 6, 472–477. [Google Scholar] [CrossRef] [PubMed]
- Gevaert, P.; Van Bruaene, N.; Cattaert, T.; Van Steen, K.; Van Zele, T.; Acke, F.; De Ruyck, N.; Blomme, K.; Sousa, A.R.; Marshall, R.P.; et al. Mepolizumab, a humanized anti–IL-5 mAb, as a treatment option for severe nasal polyposis. J. Allergy Clin. Immunol. 2011, 128, 989–995.e8. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Van Der Veen, J.; Seys, S.F.; Timmermans, M.; Levie, P.; Jorissen, M.; Fokkens, W.J.; Hellings, P.W. Real-life study showing uncontrolled rhinosinusitis after sinus surgery in a tertiary referral centre. Allergy 2016, 72, 282–290. [Google Scholar] [CrossRef] [PubMed]
- Corren, J.; Casale, T.B.; Lanier, B.; Buhl, R.; Holgate, S.; Jimenez, P. Safety and tolerability of omalizumab. Clin. Exp. Allergy 2009, 39, 788–797. [Google Scholar] [CrossRef]
- Rodrigo, G.J.; Neffen, H.; Castro-Rodriguez, J.A. Efficacy and Safety of Subcutaneous Omalizumab vs Placebo as Add-on Therapy to Corticosteroids for Children and Adults with Asthma. Chest 2011, 139, 28–35. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lanier, B.; Bridges, T.; Kulus, M.; Taylor, A.F.; Berhane, I.; Vidaurre, C.F. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J. Allergy Clin. Immunol. 2009, 124, 1210–1216. [Google Scholar] [CrossRef] [PubMed]
Variable | Omalizumab | Control |
---|---|---|
Patients n | 25 | 5 |
Male: Female | 11:14 | 3:2 |
Smoking n (%) | ||
Past smoker | 10(40) | 4(80) |
Current smoker | 2(8) | 1(20) |
Never | 13(52) | |
Allergies * n (%) | ||
Dust mites | 25(100) | 5(100) |
Cat | 15(60) | 2(40) |
Dog | 10(40) | 1(20) |
Trees | 12(48) | 3(60) |
Ragweed | 13(52) | 2(40) |
Grasses | 12(48) | 6(60) |
AERD ** n (%) | 8(32) | 3(60) |
Sinusitis Dx n (%) | ||
CRSwNP | 19(76) | 4(80) |
CRSsNP | 6(24) | 1(20) |
Previous Sinus Surgery n (%) | 18(72) | 4(80) |
Medication | Omalizumab | Control |
---|---|---|
Budesonide irrigations * | 13(52) | 3(60) |
Intranasal Corticosteroids ** | 8(32) | 2(40) |
Both (alternating) | 4(16) | - |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kilty, S.J.; Best, C.; Santucci, S.; Lasso, A.; Yang, W. Self-Reported Improvement for Chronic Rhinosinusitis Major Symptoms in Patients Treated with Omalizumab. J. Respir. 2021, 1, 1-7. https://doi.org/10.3390/jor1010001
Kilty SJ, Best C, Santucci S, Lasso A, Yang W. Self-Reported Improvement for Chronic Rhinosinusitis Major Symptoms in Patients Treated with Omalizumab. Journal of Respiration. 2021; 1(1):1-7. https://doi.org/10.3390/jor1010001
Chicago/Turabian StyleKilty, Shaun J., Corliss Best, Stephanie Santucci, Andrea Lasso, and William Yang. 2021. "Self-Reported Improvement for Chronic Rhinosinusitis Major Symptoms in Patients Treated with Omalizumab" Journal of Respiration 1, no. 1: 1-7. https://doi.org/10.3390/jor1010001